Skip to content
Clinical Trials – home
Sponsor

Adarx Pharmaceuticals Inc.

United States 5871 Oberlin Drive Suite 200, 92121-3732, United States

About the sponsor

Adarx Pharmaceuticals Inc. concentrates its research efforts on addressing critical metabolic and endocrine conditions that affect global populations. The company's investigational programs target metabolic dysfunction and associated complications, with particular emphasis on conditions affecting glucose regulation and metabolic homeostasis. Through its multi-national clinical research network, the sponsor explores therapeutic interventions designed to modulate metabolic pathways and restore physiological balance in patients with endocrine-related disorders.

  • Glucose metabolism and regulation disorders
  • Endocrine system dysfunction
  • Metabolic homeostasis restoration

The sponsor's research infrastructure spans multiple continents, facilitating diverse patient population enrollment and enabling comprehensive evaluation of therapeutic candidates across varied demographic and genetic backgrounds. This global approach supports the development of treatments with broad applicability to patients experiencing metabolic imbalances and related systemic complications.

About Specializations

Adarx Pharmaceuticals Inc. runs clinical trials in conditions such as Hereditary angioedema, Renal disorder, Immune-mediated renal disorder, Dry age-related macular degeneration, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

4 clinical trials

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

Renal disorder+1

Recruiting

A study to evaluate the safety of ADX-038 in patients with complement-mediated kidney disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ADX-038
  • Sponsor:Adarx Pharmaceuticals Inc.

A Study of ADX-324 to Prevent Attacks in Patients With Hereditary Angioedema

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ADX-324
  • Sponsor:Adarx Pharmaceuticals Inc.

A study to evaluate the safety and effectiveness of ADX-038 in adults with geographic atrophy caused by age-related macular degeneration.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ADX-038
  • Sponsor:Adarx Pharmaceuticals Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.